Market Overview:
The global metastatic bones cancer medication treatment market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of bone cancer, rising awareness about available treatments, and technological advancements in the field of oncology. Based on type, the global metastatic bones cancer medication treatment market can be segmented into chemotherapy, hormone therapy, bisphosphonates, opiate therapy, and immunotherapy. Chemotherapy is currently the most commonly used type of treatment for metastatic bone cancer and is expected to dominate the market during the forecast period. Bisphosphonates are also widely used for treating metastatic bone cancers and are expected to grow at a high rate during the forecast period. Immunotherapy is an emerging area in oncology that has shown promising results in treating various types of cancers including metastatic bone cancers; this segment is projected to grow at a high rate during the forecast period.
Product Definition:
Metastatic bones cancer medication treatment is the use of medications to treat metastatic bone tumors. The goal of treatment is to reduce pain and improve quality of life. Treatment may include chemotherapy, radiation therapy, or surgery.
Chemotherapy:
Chemotherapy is a group of medical drugs or therapy used to treat cancer. The major types of chemotherapy include alkylating agents, cytotoxic agents, plant derivatives, and antimetabolites. Alkylating agents block the production of enzymes that build up amino acids in cells; this leads to cell death.
Hormone Therapy:
Hormone therapy is a medical treatment used to replace or reduce hormones that have become deficient due to tumor growth in the body. Hormone replacement therapy includes hormone injections, oral hormone supplements, and implants. The goal of this type of treatment is to help the body produce its own hormones again. Hormone deficiency can occur as a result of tumors producing too much hormone or because the tumors can block production by certain glands.
Application Insights:
The others application segment held the largest share of metastatic bone cancer medication treatment in 2017. This is due to the increasing prevalence of cancer and growing awareness about available treatment options. For instance, as per the American Cancer Society, in 2018, around 60% of people diagnosed with osteosarcoma are alive after 5 years. Thus, increasing incidences of Osteosarcoma & Ewing¢â‚¬â„¢s tumor are leading to increased usage of metastatic bone cancer medication for its treatment which is subsequently driving growth.
Metastatic breast cancers dominated the market for hospital-based applications owing to factors such as a high prevalence rate and availability of treatments at hospitals worldwide that aid in reducing chemotherapy time significantly.
Regional Analysis:
North America dominated the global metastatic bones cancer medication treatment market in 2017. This can be attributed to the presence of a large number of key players, availability of novel drugs, and high healthcare expenditure in this region. In addition, favorable reimbursement policies for patients are also expected to drive growth during the forecast period. Asia Pacific is anticipated to witness lucrative growth over the coming years owing to increasing awareness levels about available treatments and their efficacy among patients as well as physicians.
Growth Factors:
- Increasing incidence of metastatic bones cancer
- Growing awareness about metastatic bones cancer and its treatment options
- Rising demand for better and more effective medications for metastatic bones cancer treatment
- Technological advancements in the field of metastatic bones cancer medication treatment
- Availability of government funding and support for research on metastatic bones cancer medication
Scope Of The Report
Report Attributes
Report Details
Report Title
Metastatic Bones Cancer Medication Treatment Market Research Report
By Type
Chemotherapy, Hormone Therapy, Bisphosphonates, Opiate Therapy, Immunotherapy
By Application
Hospitals, Clinics, Others
By Companies
Amgen, Merck & Co, Roche, Novartis, Eli Lilly and Company, Bayer, Fresenius Kabi, BTG plc, Boston Scientific, Medtronic
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
221
Number of Tables & Figures
155
Customization Available
Yes, the report can be customized as per your need.
Global Metastatic Bones Cancer Medication Treatment Market Report Segments:
The global Metastatic Bones Cancer Medication Treatment market is segmented on the basis of:
Types
Chemotherapy, Hormone Therapy, Bisphosphonates, Opiate Therapy, Immunotherapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen
- Merck & Co
- Roche
- Novartis
- Eli Lilly and Company
- Bayer
- Fresenius Kabi
- BTG plc
- Boston Scientific
- Medtronic
Highlights of The Metastatic Bones Cancer Medication Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Chemotherapy
- Hormone Therapy
- Bisphosphonates
- Opiate Therapy
- Immunotherapy
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Metastatic Bones Cancer Medication Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Metastatic bones cancer medication treatment is a combination of chemotherapy and radiation therapy. Chemotherapy kills cancer cells by damaging their DNA. Radiation therapy uses high-energy beams to damage the cancer cells and kill them.
Some of the key players operating in the metastatic bones cancer medication treatment market are Amgen, Merck & Co, Roche, Novartis, Eli Lilly and Company, Bayer, Fresenius Kabi, BTG plc, Boston Scientific, Medtronic.
The metastatic bones cancer medication treatment market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Metastatic Bones Cancer Medication Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Metastatic Bones Cancer Medication Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Metastatic Bones Cancer Medication Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Metastatic Bones Cancer Medication Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Metastatic Bones Cancer Medication Treatment Market Size & Forecast, 2018-2028
4.5.1 Metastatic Bones Cancer Medication Treatment Market Size and Y-o-Y Growth
4.5.2 Metastatic Bones Cancer Medication Treatment Market Absolute $ Opportunity
Chapter 5 Global Metastatic Bones Cancer Medication Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Metastatic Bones Cancer Medication Treatment Market Size Forecast by Type
5.2.1 Chemotherapy
5.2.2 Hormone Therapy
5.2.3 Bisphosphonates
5.2.4 Opiate Therapy
5.2.5 Immunotherapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Metastatic Bones Cancer Medication Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Metastatic Bones Cancer Medication Treatment Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Metastatic Bones Cancer Medication Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Metastatic Bones Cancer Medication Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Metastatic Bones Cancer Medication Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Metastatic Bones Cancer Medication Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Metastatic Bones Cancer Medication Treatment Market Size Forecast by Type
9.6.1 Chemotherapy
9.6.2 Hormone Therapy
9.6.3 Bisphosphonates
9.6.4 Opiate Therapy
9.6.5 Immunotherapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Metastatic Bones Cancer Medication Treatment Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Metastatic Bones Cancer Medication Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Metastatic Bones Cancer Medication Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Metastatic Bones Cancer Medication Treatment Market Size Forecast by Type
10.6.1 Chemotherapy
10.6.2 Hormone Therapy
10.6.3 Bisphosphonates
10.6.4 Opiate Therapy
10.6.5 Immunotherapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Metastatic Bones Cancer Medication Treatment Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Metastatic Bones Cancer Medication Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Metastatic Bones Cancer Medication Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Metastatic Bones Cancer Medication Treatment Market Size Forecast by Type
11.6.1 Chemotherapy
11.6.2 Hormone Therapy
11.6.3 Bisphosphonates
11.6.4 Opiate Therapy
11.6.5 Immunotherapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Metastatic Bones Cancer Medication Treatment Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Metastatic Bones Cancer Medication Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Metastatic Bones Cancer Medication Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Metastatic Bones Cancer Medication Treatment Market Size Forecast by Type
12.6.1 Chemotherapy
12.6.2 Hormone Therapy
12.6.3 Bisphosphonates
12.6.4 Opiate Therapy
12.6.5 Immunotherapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Metastatic Bones Cancer Medication Treatment Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Metastatic Bones Cancer Medication Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Metastatic Bones Cancer Medication Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Metastatic Bones Cancer Medication Treatment Market Size Forecast by Type
13.6.1 Chemotherapy
13.6.2 Hormone Therapy
13.6.3 Bisphosphonates
13.6.4 Opiate Therapy
13.6.5 Immunotherapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Metastatic Bones Cancer Medication Treatment Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Metastatic Bones Cancer Medication Treatment Market: Competitive Dashboard
14.2 Global Metastatic Bones Cancer Medication Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Amgen
14.3.2 Merck & Co
14.3.3 Roche
14.3.4 Novartis
14.3.5 Eli Lilly and Company
14.3.6 Bayer
14.3.7 Fresenius Kabi
14.3.8 BTG plc
14.3.9 Boston Scientific
14.3.10 Medtronic
